ESR1 and breast cancer: In this complex scenario of multiple cytokines driving endocrine resistance in HRG-overexpressing ER+ breast cancer cells, the sole blockade of IL-8 bioactivity might become inadequate in the presence of an augmented availability of IL-6 downstream of the HRG-activated HER2/HER2 oncogenic unit.